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Abstract 
Heart failure (HF) is a common and serious
comorbidity of diabetes. Oxidative stress has
been  associated  with  the  pathogenesis  of
chronic diabetic complications including car-
diomyopathy.  The  ability  of  antioxidants  to
inhibit injury has raised the possibility of new
therapeutic treatment for diabetic heart dis-
eases.  Riboflavin  constitutes  an  essential
nutrient for humans and animals and it is an
important food additive. Riboflavin, a precur-
sor of flavin mononucleotide (FMN) and flavin
adenine  dinucleotide  (FAD),  enhances  the
oxidative folding and subsequent secretion of
proteins. The objective of this study was to
investigate  the  cardioprotective  effect  of
riboflavin  in  diabetic  rats.  Diabetes  was
induced  in  30  rats  by  a  single  injection  of
streptozotocin (STZ) (70 mg /kg). Riboflavin
(20 mg/kg) was orally administered to animals
immediately after induction of diabetes and
was  continued  for  eight  weeks.  Rats  were
examined for diabetic cardiomyopathy by left
ventricular  (LV)  remadynamic  function.
Myocardial oxidative stress was assessed by
measuring the activity of superoxide dismu-
tase  (SOD),  the  level  of  malondialdehyde
(MDA) as well as heme oxygenase-1 (HO-1)
protein  level.  Myocardial  connective  tissue
growth factor (CTGF) level was measured by
Western blot in all rats at the end of the study.
In the untreated diabetic rats, left ventricular
systolic pressure (LVSP) rate of pressure rose
(+dp/dt), and rate of pressure decay (−dp/dt)
were  depressed  while  left  ventricular  end-
diastolic  pressure  (LVEDP)  was  increased,
which indicated the reduced left ventricular
contractility  and  slowing  of  left  ventricular
relaxation. The level of SOD decreased, CTGF
and HO-1 protein expression and MDA content
rose.  Riboflavin  treatment  significantly
improved left ventricular systolic and diastolic
function in diabetic rats, there were persistent
increases in significant activation of SOD and
the level of HO-1 protein, and a decrease in
the level of CTGF. These results suggest that
riboflavin  treatment  ameliorates  myocardial
function and improves heart oxidant status,
whereas raising myocardial HO-1 and decreas-
ing  myocardial  CTGF  levels  have  beneficial
effects on diabetic cardiomyopathy.
Introduction
Cardiovascular disease is the most common
serious  complication  of  diabetes  mellitus.
Prominent defects of diabetic cardiomyopathy
include the prolonged duration of contraction
and  relaxation1 and  reduced  cardiac  compli-
ance.  Although  diabetic  cardiomyopathy  has
been the subject of intensive investigation over
the last 30 years, the pathogenesis of diabetic
cardiomyopathy is still far from being fully clar-
ified. Various studies have reported that the cir-
culating markers of myocardial damage, pro-
inflammatory cytokines, calcium dysregulation,
oxidative stress and atherogenic lipids are ele-
vated in diabetic patients.2-9
Metabolically, the diabetic heart is charac-
terized by diminished glucose utilization and
increased  fatty  acid  oxidation  resulting  in
lipid  accumulation  in  the  myocardium.10-11
This  myocardial  lipotoxicity  results  in  alter-
ations in the inflammatory cytokine levels and
evokes a cascade of disparaging changes that
leads to cardiac damage.
Numerous studies have demonstrated that
the pivotal mediator for the pathogenesis of
diabetes and its cardiovascular complications
is  oxidative  stress.12,13 The  increase  in  the
level  of  oxidative  stress  results  from  an
increased  generation  of  reactive  oxygen
species (ROS) or from a reduction in antioxi-
dants, which was thought to contribute to the
initiation and progression of cardiac dysfunc-
tion  and  remodeling  of  the  extracellular
matrix in the heart.14-17 ROS are continuously
produced  in  most  cells  under  physiological
conditions, and their levels are regulated by a
number  of  antioxidant  enzymes,  such  as
superoxide dismutase, glutathione peroxidase
and catalase, as well as by other non-enzymat-
ic antioxidants. The ability of antioxidants to
inhibit these injuries has raised the possibili-
ty of new therapeutic treatment for diabetes
and its complication. Heme oxygenase-1 (HO-
1) is a ubiquitously expressed stress inducible
enzyme that catabolizes heme into bilirubin,
carbon  monoxide  (CO)  and  iron.18 The  by-
products of heme catabolism exert pleiotropic
cytoprotective effects in the heart. Bilirubin is
a  powerful  antioxidant,19 and  CO  exerts
vasodilatory, anti-inflammatory and anti-pro-
liferative effects.20 On another level, antioxi-
dant  administration  has  been  reported  to
show  beneficial  effects  on  parameters  of
oxidative stress and cardiovascular functions
in experimental diabetes.21
Connective  tissue  growth  factor  (CTGF),
cysteine-rich  glycoproteins,  is  an  important
stimulant of fibrosis,22 and is currently sug-
gested to be an important downstream ampli-
fier of the effects of the profibrogenic master
cytokine  transforming  growth  factor  (TGF)-
β.23,24 For  cardiac  fibrotic  responses  to  dia-
betes, attention has been paid recently to the
role of CTGF, since several studies indicated
that renal and cardiac fibrosis may not be fully
dependent on TGF-β, but may be predominant-
ly dependent on CTGF.25,26 Therefore, an ideal
approach to prevent DCM may target reducing
CTGF expression.
Riboflavin is a precursor of flavin mononu-
cleotide  (FMN)  and  flavin  adenine  dinu-
cleotide (FAD), which serve as coenzymes for
numerous  oxidases  and  dehydrogenases  in
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eukaryotic cells.27 For example, FAD-depend-
ent Ero1 and sulfhydryl oxidases participate in
the  oxidative  folding  (formation  of  disulfide
bonds) of secretory proteins in the endoplas-
mic  reticulum.28-31 Riboflavin  deficiency
impairs the oxidative folding and subsequent
secretion  of  proteins  in  human  cell  cul-
tures.30,31
However, there has been no documentation
concerning the protection of riboflavin against
diabetes-induced cardiac dysfunction to date.
In the current study, we investigated the effect
of riboflavin on diabetic cardiomyopathy in the
STZ-induced  diabetic  rats.  Recent  studies
show that HO-1 is a stress-induced protein. It
protects against tissue injury through multiple
mechanisms  including  anti-oxidation,  anti-
inflammation, and anti-apoptosis.32,33
Therefore, to evaluate myocardial oxidative
stress  in  diabetic  cardiac  complications,  we
chose  to  investigate  the  possible  effect  of
riboflavin  on  circulating  markers  of  cardiac
damage (CK, LDH), oxidative stress (lipid per-
oxides), and antioxidant enzyme (heme oxy-
genase-1, superoxide dismutase) in relation to
left  ventricular  (LV)  hemodynamic  function
during  type  I  diabetic  cardiomyopathy  using
the well-characterized rat streptozotocin (STZ)
model of type I diabetes. To determine the car-
dioprotective  effects  against  diabetic  cardio-
vascular disease, we orally administered STZ-
diabetic rats with riboflavin. We also investi-
gated the effects of riboflavin on heart levels of
CTGF.
Materials and Methods
Experimental animals
Sprague-Dawley  rats  weighing  200±20  g
were  provided  by  the  Experimental  Animal
Center in Wannan Medical College and housed
in a standard animal facility under controlled
environmental conditions at room temperature
22±2°C and 12-h light-dark cycle. All experi-
ments were performed in accordance with the
Guide  for  the  Care  and  Use  of  Laboratory
Animals of the Chinese National Institutes of
Health.
Induction of diabetes
Diabetes was induced by a single i.p. injec-
tion of STZ (70 mg/kg) dissolved in 0.1M cit-
rate buffer (pH 4.5) in male Sprague-Dawley
rats (180-220 g). The control group rats were
treated with the same volume citrate buffer.
Diabetes  was  confirmed  at  72  h  after  STZ
injection by measuring the glucose concentra-
tions of peripheral blood obtained from the tail
vein  (One  Touch  SureStep  Meter,  LifeScan,
CA, USA) and weekly thereafter. Insulin was
not  administered,  and  all  animals  had  free
access to food and water. Diabetes was diag-
nosed by a sustained glucose concentration of
more than 15 mmol/l.
Experimental protocols and
riboflavin treatment
Control  and  diabetic  rats  were  randomly
assigned to three main experimental groups (8
animals per group) immediately after confir-
mation of STZ-induced diabetes: control rats
received  the  control  diet;  diabetic  rats,
received  the  control  diet;  riboflavin  rats,
received orally administered riboflavin (20 mg
kg–1 per day) and the control diet.
Cardiac function
After eight weeks of drug dosing, rats were
anesthetized  with  sodium  pentobarbital  (50
mg/kg i.p.). The right carotid artery was cannu-
lated  with  a  Millar  mininature  catheter  and
advanced into the aorta to record arterial pres-
sure. The aortic catheter was then advanced
into the left ventricle to record left ventricular
systolic pressure (LVSP), left ventricular devel-
oped  pressure  (LVDP),  left  ventricular  end
diastolic pressure (LVEDP), maximal rate of
rise/fall  left  ventricle  pressure  development
and  decline  (±dP/dtmax).  All  pressure  data
were recorded on MedLab data acquisition sys-
tem (Nanjing MedEase Co., Nanjing, China).
Fasting blood samples and hearts were then
collected from all the groups of rats for further
studies.
Biochemical analyses of blood samples
The levels of serum triacylglycerol (lipopro-
tein  lipase  method),  cholesterol  (cholesterol
oxidase  method),  HDL  (polyanion
polymer/detergent  method),  LDL  (catalase
method),  creatine  kinase  (CK;  peroxydase
method) and lactate dehydrogenase (LDH; lac-
tic acid method) were measured as previously
described.34
Measurement of myocardial oxida-
tive stress
Left ventricular homogenate (10%, w/v) was
prepared with 0.1 M PBS and centrifuged at
12,000 g for 10 min. The supernatant was used
to determine SOD activity and MDA levels with
commercially  available  kits  (Nanjing
Jiancheng Bioengineering Institute).
Western blotting
Left  ventricles  (0.2  g)  were  lysed  and
homogenized in 2 mL of lysis buffer (10 mM
Tris-buffered saline, 1 mM EDTA, 1 mM EGTA,
2 mM sodium orthovanadate, 0.2 mM PMSF, 2
μg/mL leupeptin, 2 μg/mL aprotinin, and 1%
Triton X-100) for 30 min on ice and cleared by
centrifugation at 12,000 g for 15 min at 4°C.
Total protein concentration was determined in
the supernatant using the Bradford assay (Bio-
Rad  Laboratories,  Hercules,  CA,  USA).  For
each  lane,  equal  amounts  of  protein  were
mixed with sodium dodecyl sulfate (SDS) sam-
ple buffer and boiled for 5 min. Samples were
separated  on  a  10%  sodium  dodecyl  sul-
fatepolyacrylamide gel and then transferred to
0.2-μm  nitrocellulose  membrane.
Nitrocellulose blots were blocked by incubation
in  TBST  (10  mM  Tris-HCl,  pH  7.5,  150  mM
NaCl, and 0.1% Tween 20) containing 5% non-
fat milk for 1 h at room temperature and then
incubated with a rabbit polyclonal anti-HO-1,
CTGF, β-actin antibody (1:500 dilution; Wuhan
Boster  Biotechnologies,  Wuhan,  China)
overnight at 4°C. After 3 washing steps, a sec-
ondary anti-rabbit antibody (1:10,000 dilution;
Sigma Chemical Co, St. Louis, MO, USA) was
added and incubated for 1 h. After being rinsed
three times with wash buffer, the reaction was
visualized by DAB (Bio Basic Inc., Canada).
The relative amounts of the bands were quan-
tified by densitometry using image software.
Statistical analysis
Data  are  expressed  as  the  mean  ±  SEM.
Group  means  were  compared  by  one-way
analysis  of  variance  (ANOVA).  Comparison
between  two  groups  was  performed  by
Student’s t-test. Values of P<0.05 were consid-
ered significant.
Results
Change in body weight and heart
weight/body weight ratio after
riboflavin treatment
After STZ administration, animals showed
similar  hyperglycemia  in  all  experimental
groups. There was no change in blood glucose
levels in diabetic rats treated with riboflavin
who also showed a significant decrease in body
weight  compared  with  controls  (Table  1).
However, the results in Table 1 also show an
increase heart weight/body weight ratio in the
STZ-diabetic animals. Treatment of riboflavin
prevented body weight loss in diabetic rats as
compared with the untreated rats. In addition,
diabetic rats had increased heart weight/body
weight ratio, a marker for the development of
diabetic  cardiomyopathy,  and  this  ratio  was
significantly  decreased  by  treatment  with
riboflavin (Table 1).
Effects of riboflavin on cardiac
function
Cardiovascular function was evaluated by LV
hemodynamic analysis before rats were sacri-
ficed (Table 2). Left ventricular hemodynamic
parameters were measured in control and dia-Clinical Investigation
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betic rats treated with and without riboflavin
for  assessment  of  ventricular  performance.
Table 2 shows left ventricular pressure and left
ventricular  dP/dt  recordings  obtained  from
control and diabetic rats treated with and with-
out  riboflavin.  The  untreated  diabetic  rats
show a lower left ventricular systolic pressure
(LVSP),  left  ventricular  developed  pressure
(LVDP), and a higher left ventricular end dias-
tolic pressure (LVEDP) compared to the control
rats (Table 2). In addition, compared with the
control rats, the untreated diabetic rats also
show a depressed left ventricular ±dP/dtmax.
The diabetic rats treated with riboflavin show
an increased LVSP, LVDP, and a reduced LVEDP
concomitant  with  a  higher  left  ventricular
±dP/dtmax. Heart rate (HR) in untreated dia-
betic  rats  was  significantly  decreased.
Riboflavin treatment increased HR (Table 2).
Effects of riboflavin on CK and LDH
Compared  to  the  controls,  the  circulating
markers of cardiac damage in STZ diabetic rats
showed a significant increase in the levels of
serum  CK  and  LDH.  However,  the  riboflavin
treatment to the diabetic rats markedly reduced
the levels of LDH and CK when compared with
the untreated diabetic rats (Figure 1).
Effects of riboflavin on serum lipid
profile
Riboflavin had a significant effect on lower-
ing triglyceride, cholesterol and LDL levels and
increasing HDL levels in diabetic rats (Table
3). All these levels were completely normalized
after riboflavin treatment which suggests that
riboflavin is far more effective in maintaining
the lipid profile near to that of the control in
this animal model of diabetes.
Antioxidant effects of riboflavin
Lipid peroxide formation (MDA), which is
a direct marker for oxidative stress, signifi-
cantly increased the cardiac tissue of the STZ
group compared with the control (Figure 2).
Riboflavin  treatment  significantly  reduced
the  levels  of  lipid  peroxidation  which  were
very  close  to  those  of  the  control  group
(Figure 2). The level of SOD was significant-
ly  depressed  in  the  diabetic  rats  compared
with  controls  (Figure  2).  Treatment  with
riboflavin significantly increased SOD heart
activity in diabetic rats.
Changes in HO-1, and CTGF pro-
tein by riboflavin treatment in dia-
betic rats
Western blot analyses showed an accumu-
lation of HO-1 protein in diabetic rats com-
Table 1. General characteristics of control and diabetic rats.
Control rats Diabetic rats Riboflavin rats
Body weight (g) 398.6±18.7 169.5±12.6** 230.4±14.7°
Heart weight (g) 1.33±0.23 1.11±0.20* 0.97±0.17
Heart weight/body weight (103) 3.35±0.49 6.57±1.37** 4.22±0.76°
Blood glucose (mmol/l) 4.91±0.46 24.54±2.73** 22.27±1.50
Values are expressed as mean ± SD of 8 samples from each group. *P<0.05, **P<0.01, significant difference to control rats. °P<0.01, signifi-
cant difference to diabetic rats.
Table 2. Effect of riboflavin treatment on left ventricular hemodynamic parameters in
control and diabetic groups of animals.
Control rats Diabetic rats Riboflavin rats
HR(bpm) 416±8.6 309±19.2** 338±13.1°
LVSP(mmHg) 136.1±10.1 76.4±7.9** 126.5±10.2°
LVEDP(mmHg) 1.70±0.50 7.73±1.01** 3.82±0.65°
LVDP(mmHg) 114.0±9.7 62.8±7.9** 83.7±8.4°
+ dP/dtmax 4229±118 2586±92**  3401±103°
- dP/dtmax 4135±143 2463±101** 3310±82°
Values are expressed as mean ± SD of 8 samples from each group. *P<0.05, **P<0.01, significant difference to control rats. °P<0.01, signifi-
cant difference to diabetic rats.
Table 3. Effects of riboflavin on serum lipid profile in control and diabetic groups of ani-
mals.
Group TC(mmol/L) TG(mmol/L) LDL(mmol/L) HDL(mmol/L)
Control rats 1.38±0.26 0.67±0.13 1.75±0.36 1.12±0.15
Diabetic rats 5.31±0.77** 2.23±0.28** 8.89±0.94** 0.34±0.06**
Riboflavin rats 2.63±0.43° 1.17±0.20° 3.81±0.88° 0.57±0.09°
Values are expressed as mean ± SD of 8 samples from each group. *P<0.05, **P<0.01, significant difference to control rats. °P<0.01, signifi-
cant difference to diabetic rats.
Figure 1. Effect of riboflavin on the level of
CK  and  LDH  in  serum  after  treatment
with riboflavin in diabetic rats. All values
represent mean±SEM (n=8). **P<0.01, sig-
nificant  difference  to  control  rats;
##P<0.01, significant difference to diabet-
ic rats. CK, creatine kinase; LDH, lactate
dehydrogenase.
Figure 2. Effect of riboflavin on the level of
MDA (a) and SOD (b) in diabetic rats. All
the  values  represent  mean±SED  (n=8).
**P<0.01, significant difference to control
rats; ## P<0.01, significant difference to
diabetic rats. SOD, superoxide dismutase;
MDA, malondialdehyde.Clinical Investigation
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pared  with  normal  control  rats  (Figure.  3).
Riboflavin treatment led to a strong upregula-
tion  of  HO-1  protein  compared  with  the
untreated rats (Figure 3). To determine the
effects  of  riboflavin  on  cardiac  fibrotic
response  to  diabetes,  expression  of  cardiac
CTGF was examined by Western blot. Results
showed that CTGF was significantly increased
in cardiac tissue from diabetic rats (Figure 3).
Riboflavin  treatment  significantly  prevented
diabetes-caused upregulation of CTGF.
Discussion 
Diabetes  is  a  metabolic  syndrome  with  a
cluster  of  common  clinical  disorders  that  is
related with an increased risk for cardiovascu-
lar  disease.38 Cardiovascular  complications
remain the leading cause of diabetes-related
mortality  and  morbidity.36 A  specific  disease
termed as diabetic cardiomyopathy increases
the risk for cardiac dysfunction and heart fail-
ure independently of other risk factors such as
coronary artery disease and hypertension, as
evidenced by compelling epidemiological and
clinical data.37,38 Despite the potential impor-
tance  of  this  disease  entity,  the  underlying
mechanisms  are  still  not  well  understood.
Dyslipidemia, oxidative stress and inflamma-
tory injury are important interrelated factors
responsible for the development of cardiomy-
opathy as they are known to promote the pro-
gression  of  premature  atherosclerosis,  coro-
nary insufficiency and myocardial infarction.39
Riboflavin,  a  precursor  of  flavin  mononu-
cleotide  (FMN)  and  flavin  adenine  dinu-
cleotide (FAD), prevents cardiac damage and
enhances  the  oxidative  folding  and  subse-
quent secretion of proteins.40-42 However, the
effect of riboflavin on the antioxidant proper-
ties and altered lipid profile in experimental
models of diabetes has not yet been studied. In
the present study, we extensively evaluated the
effect of riboflavin on cardiac damage. 
Diabetic  cardiomyopathy  characterized  by
diastolic  dysfunction  and  left  ventricular
hypertrophy is usually the terminal condition
of heart in diabetes.43 Our results indicate that
8-week treatment of riboflavin in diabetic rats
proved to be beneficial as it restrained the pro-
gression  of  the  metabolic  disorders  of  dia-
betes. The STZ diabetic rats showed elevated
blood glucose levels. Also, there was a notable
increase in the HW/BW ratio which signifies
cardiac hypertrophy. Metabolically, the diabetic
heart is characterized by diminished glucose
utilization and increased fatty acid oxidation
resulting  in  lipid  accumulation  in  the
myocardium.10,11 Riboflavin  remarkably
improved  lipid  profile.  Riboflavin  treatment
showed  a  distinct  positive  effect  on  HW/BW
ratio indicating that riboflavin was able to pre-
vent cardiac hypertrophy which usually sets in
as a result of diastolic dysfunction secondary
to diabetes. The untreated STZ-diabetic ani-
mals showed significant depressions in LVSP,
+dP/dt, and −dP/ dt and concomitant increases
in LVEDP. These hemodynamic alterations in
the  untreated  STZ-diabetic  rats  demonstrate
abnormal left ventricular systolic and diastolic
function that is the hallmark of diabetic car-
diomyopathy. Riboflavin treatment attenuated
these hemodynamic changes. 
Increases  in  levels  of  circulating  cardiac
damage markers, such as CK and LDH, repre-
sent  a  powerful  and  sensitive  predictor  of
increased  cardiac  complications.44,45 In  the
present study, riboflavin-treated diabetic rats
showed a significant improvement in levels of
these  circulating  cardiac  damage  markers.
This indicates that riboflavin prevents cardiac
damage  and  has  beneficial  properties.  The
decrease in the cardiac damage markers in the
diabetic  rats  upon  riboflavin  treatment  sug-
gested that the riboflavin treatment reduces
the risk of metabolic disorders associated with
diabetics.
Increased  oxidative  stress  and  an  altered
antioxidant pool have been implicated in both
clinical  and  experimental  type  1  diabetes.14
The results from our study showed that an STZ
induced  diabetic  condition  resulted  in  an
increase in the lipid peroxidation and protein
carbonylation  which  are  direct  indicators  of
systemic oxidative stress. This was in conjunc-
tion  with  depletion  of  superoxide  scavenger
SOD  and  an  increase  in  lipid  peroxidation
product MDA. Riboflavin treatment in the STZ-
diabetic  rats  reduced  the  formation  of  lipid
peroxides  and  carbonyl  content  and  also
restored the levels of SOD. Heme oxygenase-1
(HO-1), the inducible isoform of the HO sys-
tem, is a rate-limiting enzyme which converts
heme into equimolar amounts of iron, carbon
monoxide and biliverdin. HO-1 is thought to
have  antioxidant  and  cytoprotective  roles.31
Riboflavin  treatment  significantly  increased
the level of myocardial HO-1 in the STZ-diabet-
ic  rats.  This  positive  beneficial  effect  of
riboflavin could be directly attributable to its
antioxidative  nature  which  is  in  agreement
with previous findings.40-42
Apart from the altered metabolic condition,
diabetes is also an inflammation-prone condi-
tion.  Hyperglycemia-induced  ROS  stimulates
signal transduction to instigate inflammatory
cytokines, e.g. TNF-α, IFN-γ and TGF-β.46 This
leads to systemic inflammation, cardiac dys-
function and exacerbates the severity of dia-
betes.47 CTGF, a recently discovered cytokine,
has been demonstrated to play an important
role  in  fibrotic  response  through  a  TGF-β1-
dependent or independent pathway.25,26 CTGF
acts as a cofactor with TGF-β to induce fibrob-
lasts to become myofibroblasts that deposit col-
lagen, ultimately resulting in organ scarring
and dysfunction, and in the most severe forms,
organ failure and death. Indeed, CTGF levels in
tissue, blood or vitreal fluid have been shown
to  correlate  with  the  degree  and  severity  of
fibrosis  in  many  diseases.48 Other  studies
showed  that  CTGF  also  exhibited  prohyper-
trophic  properties  on  cardiomyocytes.49
Furthermore,  CTGF  has  been  proposed  as  a
heart  failure  biomarker.43-44 Stress  induced
CTGF  in  cultured  cardiomyocytes.50,51 In  the
present study, riboflavin-treated diabetic rats
showed  effective  suppression  of  CTGF.  The
results  strongly  indicate  that  riboflavin  is  a
potential  agent  against  diabetes-associated
systemic fibrosis.
In  our  study,  the  altered  lipid  profile
Figure  3. Western  blot  of  HO-1  (a)  and
CTGF  (b)  in  heart  after  treatment  with
riboflavin in diabetic rats. HO-1and CTGF
were normalized with respect to actin in
respective  controls.  Similar  results  were
obtained in four independent sets of exper-
iments.  All  the  values  represent
mean±SEM  (n=4).  **P<0.01,  significant
difference to control rats; ##P<0.01, signif-
icant  difference  to  diabetic  rats.  HO-1,
heme oxygenase-1; CTGF, connective tis-
sue growth factor.Clinical Investigation
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observed  in  the  diabetic  condition  was  also
abrogated by riboflavin treatment. Riboflavin
improved the serum cholesterol, triglycerides,
LDL  and  HDL.  These  findings  suggest  that
riboflavin  possesses  lipid  lowering  activities
due to its unique anti-atherogenic properties
which contribute also to its cardiovascular pro-
tective actions. This is the first report to evalu-
ate the positive effect of riboflavin on lipid pro-
file in STZ-diabetic rats.
Limitations
This study has several limitations. The sam-
ple size was relatively small. This preliminary
result must be verified in a more numerous
population, and on a long-term basis. Although
myocardial oxidative stress was measured, we
did not provide more detailed mechanisms.
Conclusions
In summary, the present findings show that
treatment  with  riboflavin  may  attenuate  the
progressive  cardiac  dysfunction  and  myocar-
dial oxidative stress in a murine model of dia-
betic cardiomyopathy. The beneficial effect of
riboflavin  is  a  result  of  its  inhibition  of
myocardial oxidative stress processes through
its  potential  antioxidant  properties.  Our
results  show  that  riboflavin  administration
may  exert  beneficial  effects  in  diabetic  car-
diomyopathy  by  increasing  antioxidant  and
decreasing  CTGF  levels.  We  suggest  that  it
might  be  useful  to  re-explore  the  role  of
antioxidant  therapy  given  immediately  after
the  diagnosis  of  type  I  diabetes  mellitus  to
reduce the risk of future cardiovascular com-
plications.
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